排序方式: 共有39条查询结果,搜索用时 125 毫秒
1.
Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits. 相似文献
2.
Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits. 相似文献
3.
目的探讨重组人血管内皮抑素联合TC方案(多西紫杉醇+环磷酰胺)治疗晚期乳腺癌的近期疗效、安全性,观察治疗前、后血清血管内皮生长因子(vascular endothelial growth factor,VEGF)水平变化。方法晚期乳腺癌患者56例,随机分为观察组和治疗组各28例,治疗组应用TC方案化疗,观察组在治疗组基础上给予重组人血管内皮抑素,2组均21d为1个周期,治疗2个周期后评价不良反应与疗效。分别于治疗前及治疗2个周期后检测2组血清VEGF水平,并与同期28例健康体检者(对照组)比较。结果观察组有效率(75.0%)高于治疗组(46.4%)(P〈0.05),骨髓抑制、恶心呕吐、脱发发生率与治疗组比较差异无统计学意义(P〉0.05);观察组、治疗组治疗前血清VEGF水平均高于对照组(P〈0.05),观察组治疗后血清VEGF水平低于治疗前与治疗组(P〈0.05),治疗组治疗后血清VEGF水平与治疗前比较差异无统计学意义(P〉0.05)。结论重组人血管内皮抑制素联合TC方案治疗晚期乳腺癌可提高疗效,降低血清VEGF水平,且不增加化疗的不良反应。 相似文献
4.
Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits. 相似文献
5.
目的:分析紫杉醇联合复方苦参注射液同步放化疗对食管癌老年患者的近期疗效及毒副作用。方法:选取于本院诊治的食管癌老年患者118例,随机分为观察组与对照组,各59例。对照组采用紫杉醇同步放化疗,观察组在对照组的基础上静脉注射复方苦参注射液至放化疗结束,放化疗时间共计3个月,随访1年。比较2组患者近期临床疗效、治疗前后免疫功能变化、治疗及随访期间毒副反应发生情况。结果:治疗3个月后观察组DCR(96.61%)显著高于对照组(67.80%)(P0.05);随访期结束后观察组生存率(86.44%)显著高于对照组(67.80%)(P0.05);治疗后观察组全血CD_4~+比例、CD_4~+/CD_8~+显著高于治疗前及对照组,全血CD_8~+比例显著低于治疗前及对照组(P0.01);治疗后对照组血清IgG、IgA及IgM水平显著低于治疗前及观察组(P0.01);治疗及随访期间观察组Ⅰ~Ⅱ级食欲下降、呕吐、白细胞下降、放射性食管炎及Ⅲ~Ⅳ级呕吐的发生率均显著低于对照组(P0.05)。结论:紫杉醇联合复方苦参注射液同步放化疗治疗老年食管癌有效控制病情进展,降低毒副反应,提升患者对治疗的耐受性及生存率。 相似文献
6.
目的:观察泮托拉唑联合托烷司琼、地塞米松防治卡培他滨联合奥沙利铂(XELOX)方案所致消化道反应的疗效和不良反应。方法:将98例使用XELOX化疗方案的晚期胃癌肿瘤患者随机分为两组,干预组化疗期间给予托烷司琼、泮托拉唑和地塞米松,对照组化疗期间给予托烷司琼和地塞米松,比较两组的临床效果与药物不良反应。结果:干预组在预防肿瘤患者食欲不振、抑制恶心、呕吐等方面明显优于对照组(P〈0.01),两组其他不良反应发生率无明显差异(P〉0.05)。结论:泮托拉唑联合托烷司琼、地塞米松防治XELOX方案化疗所致消化道反应疗效较好,值得临床应用。 相似文献
7.
盐酸羟考酮缓释片治疗中重度癌痛临床观察 总被引:1,自引:0,他引:1
目的观察盐酸羟考酮缓释片治疗中重度癌痛的疗效、不良反应及对患者生活质量改善情况。方法120例中重度癌痛患者,均口服盐酸羟考酮缓释片,初始剂量为10~20rag/次,1次/12h,并根据疼痛缓解程度调整剂量至理想镇痛。用药14d后观察患者疼痛数字评分法(numericalratingscale,NRS)评分、疼痛缓解率、生活质量改善及不良反应发生情况。结果治疗后NRS评分(1.46±1.13)低于治疗前(6.37±1.63)(P〈O.05);治疗后疼痛完全缓解64例,部分缓解52例,疼痛总缓解率为96.7%;治疗后生活质量评分较治疗前增高(P〈O.05);不良反应轻。结论盐酸羟考酮缓释片治疗中重度癌痛效果满意,可改善患者生活质量。 相似文献
8.
9.
Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits. 相似文献
10.
目的:通过观察粉防己碱对人结肠癌细胞株HT-29增殖与凋亡的影响,初步探讨粉防己碱对结肠癌的体外抗肿瘤效应。方法:采用MTT比色法观察粉防己碱对HT-29细胞的增殖抑制效应,利用细胞DNA琼脂糖凝胶电泳及细胞凋亡荧光染色法检测粉防己碱诱导肿瘤细胞凋亡的作用,以免疫细胞化学法检测粉防己碱对Bcl-2和BAX表达水平的影响。结果:MTT比色法显示粉防己碱对人结肠癌细胞株HT-29增殖有抑制作用,其抑制效应具有剂量依赖的特点,细胞凋亡荧光染色法、琼脂糖凝胶电泳表明粉防己碱可诱导HT-29细胞凋亡,免疫细胞化学法显示粉防己碱上调BAX基因表达,下调Bcl-2基因表达。结论:粉防己碱对人结肠癌细胞株HT-29增殖的抑制效应具有剂量依赖性,并可诱导细胞凋亡,其抗肿瘤效应可能与凋亡相关基因表达的调控有关。 相似文献